Zacks Investment Research upgraded shares of China Biologic Products (NASDAQ:CBPO) from a strong sell rating to a hold rating in a research note issued to investors on Tuesday.
According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “
A number of other research analysts also recently issued reports on the company. ValuEngine raised China Biologic Products from a strong sell rating to a sell rating in a report on Monday, June 18th. BidaskClub downgraded China Biologic Products from a hold rating to a sell rating in a report on Friday, September 28th. Finally, Credit Suisse Group downgraded China Biologic Products from an outperform rating to a neutral rating in a report on Monday, August 6th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. The company has an average rating of Hold and an average price target of $101.00.
China Biologic Products (NASDAQ:CBPO) last issued its earnings results on Friday, August 3rd. The biopharmaceutical company reported $1.17 EPS for the quarter, missing the Zacks’ consensus estimate of $1.26 by ($0.09). The firm had revenue of $120.40 million during the quarter, compared to analysts’ expectations of $116.21 million. China Biologic Products had a net margin of 15.89% and a return on equity of 14.00%. China Biologic Products’s quarterly revenue was up 34.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.35 EPS. As a group, sell-side analysts anticipate that China Biologic Products will post 3.71 earnings per share for the current year.
Large investors have recently made changes to their positions in the business. Fox Run Management L.L.C. acquired a new position in China Biologic Products in the third quarter valued at approximately $262,000. Myriad Asset Management Ltd. acquired a new position in shares of China Biologic Products during the 2nd quarter worth approximately $348,000. Parametrica Management Ltd acquired a new position in shares of China Biologic Products during the 2nd quarter worth approximately $386,000. Jane Street Group LLC acquired a new position in shares of China Biologic Products during the 2nd quarter worth approximately $461,000. Finally, Kassirer Asset Management Corp acquired a new position in shares of China Biologic Products during the 2nd quarter worth approximately $596,000. 44.22% of the stock is owned by institutional investors.
About China Biologic Products
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
Featured Story: Should You Consider an Index Fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.